BioCryst Pharmaceuticals, Inc. (BCRX)

NASDAQ: BCRX · Real-Time Price · USD

Compare

6.78

+0.03 (0.44%)

At close: Jan 14, 2026, 4:00 PM EST

6.79

+0.01 (0.15%)

After-hours: Jan 14, 2026, 7:58 PM EST

BioCryst Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Revenue	599.82	450.71	331.41	270.83	157.17	17.81	Upgrade
Revenue Growth (YoY)	45.38%	36.00%	22.37%	72.31%	782.38%	-63.53%	Upgrade
Cost of Revenue	189.36	185.92	216.65	259.89	216.07	124.64	Upgrade
Gross Profit	410.45	264.79	114.76	10.94	-58.9	-106.83	Upgrade
Selling, General & Admin	333.09	266.07	213.54	159.37	118.82	62.9	Upgrade
Operating Expenses	333.09	266.07	213.54	159.37	118.82	62.9	Upgrade
Operating Income	77.36	-1.28	-98.78	-148.44	-177.72	-169.73	Upgrade
Interest Expense	-89.19	-98.52	-108.24	-99.09	-59.29	-14.5	Upgrade
Interest & Investment Income	11.35	14.75	15.78	5.13	0.06	0.53	Upgrade
Currency Exchange Gain (Loss)	-0.63	-0.64	-1.04	-1.98	-0.7	-0.97	Upgrade
EBT Excluding Unusual Items	1.56	-85.69	-192.28	-244.38	-237.65	-184.67	Upgrade
Merger & Restructuring Charges	-1.26	-1.26	-3.38	-	-	-	Upgrade
Gain (Loss) on Sale of Investments	-	-	-	-	0	-	Upgrade
Asset Writedown	-	-	-1.55	-	-	-	Upgrade
Legal Settlements	-	-	-	-	-	3.87	Upgrade
Other Unusual Items	-6.91	-	-29.02	-	55.84	-2.01	Upgrade
Pretax Income	-6.62	-86.95	-226.23	-244.38	-181.81	-182.81	Upgrade
Income Tax Expense	2.16	1.93	0.31	2.73	2.25	-	Upgrade
Net Income	-8.78	-88.88	-226.54	-247.12	-184.06	-182.81	Upgrade
Net Income to Common	-8.78	-88.88	-226.54	-247.12	-184.06	-182.81	Upgrade
Shares Outstanding (Basic)	209	207	192	186	179	167	Upgrade
Shares Outstanding (Diluted)	209	207	192	186	179	167	Upgrade
Shares Change (YoY)	1.84%	7.54%	3.38%	3.79%	7.08%	44.70%	Upgrade
EPS (Basic)	-0.04	-0.43	-1.18	-1.33	-1.03	-1.09	Upgrade
EPS (Diluted)	-0.05	-0.43	-1.18	-1.33	-1.03	-1.09	Upgrade
Free Cash Flow	47.86	-53.14	-97.31	-163.2	-144.54	-135.62	Upgrade
Free Cash Flow Per Share	0.23	-0.26	-0.51	-0.88	-0.81	-0.81	Upgrade
Gross Margin	68.43%	58.75%	34.63%	4.04%	-37.48%	-	Upgrade
Operating Margin	12.90%	-0.28%	-29.81%	-54.81%	-113.07%	-952.90%	Upgrade
Profit Margin	-1.46%	-19.72%	-68.36%	-91.25%	-117.11%	-1026.35%	Upgrade
Free Cash Flow Margin	7.98%	-11.79%	-29.36%	-60.26%	-91.97%	-761.41%	Upgrade
EBITDA	80.43	1.73	-95.91	-146.18	-176.83	-168.98	Upgrade
EBITDA Margin	13.41%	0.39%	-28.94%	-53.98%	-112.51%	-	Upgrade
D&A For EBITDA	3.07	3.01	2.87	2.25	0.89	0.75	Upgrade
EBIT	77.36	-1.28	-98.78	-148.44	-177.72	-169.73	Upgrade
EBIT Margin	12.90%	-0.28%	-29.81%	-54.81%	-113.07%	-	Upgrade
Revenue as Reported	-	-	-	-	-	17.81	Upgrade
Advertising Expenses	-	13.57	14.4	14.89	5.71	6.57	Upgrade

Updated Nov 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q